Treatment of diabetic vasculopathy: an overview

References

• International Diabetes Federation (IDF). Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009.
   Google Scholar
• Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulindependent diabetes mellitus. Ann Intern Med. 1996;124 (1 Pt 2):136–145.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Management of dyslipidemia in adults with diabetes. American Diabetes Association: Clinical Practice Recommendations 1999. Diabetes Care. 1999;22:556–559.
   Web of Science ®Google Scholar
• Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman AR. Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. Diabetes Res Clin Pract. 2008;80(2):253–258.
   Web of Science ®Google Scholar
• Giannattasio C, Failla M, Capra A, et al. Increased arterial stiffness in normoglycemic normotensive offspring of type 2 diabetic parents. Hypertension. 2008;51(2):182–187.
   Web of Science ®Google Scholar
• Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman AR. Increased arterial stiffness in normoglycaemic offspring of newly diagnosed, never treated type 2 diabetic and impaired glucose tolerance parents. Br J Diabetes Vasc Dis. 2009;9:65–68.
   Google Scholar
• Word Health Organisation. Diabetes. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed Jun 2011.
   Google Scholar
• Williams R, van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45(7):S13-S17.
   Web of Science ®Google Scholar
• Jonsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45(7):S5-S12.
   PubMed Web of Science ®Google Scholar
• Zimmet P, Shaw J, Alberti KG. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med. 2003;20(9):693–702.
   Web of Science ®Google Scholar
• American Heart Association. Cardiovascular Disease and Diabetes. Available from: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp. Accessed October 12, 2011.
   Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2005.
   Google Scholar
• Rahman S, Ismail AA, Rahman AR. Treatment of diabetic vasculopa- thy with rosiglitazone and ramipril: Hype or hope? Int J Diabetes Dev Ctries. 2009;29(3):110–117.
   Web of Science ®Google Scholar
• American Diabetes Association. Position statement: Diabetes mellitus and exercise. Diabetes Care. 1990;13(7):804–805.
   Web of Science ®Google Scholar
• Dela F, Ploug T, Handberg A, et al. Physical training increases muscle GLUT 4 protein and mRNA in patients with NIDDM. Diabetes. 1994;7:862–865.
   Google Scholar
• Zanchetti A.. Aspirin and antiplatelet drugs in the prevention of cardiovascular complications of diabetes. In: Mogensen CE, editor. Pharmacotheraphy of Diabetes: New Developments. Improving Life and Prognosis for Diabetic Patients. New York, NY: Springer; 2007: 211–218.
   Google Scholar
• IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 2005.
   Google Scholar
• Yeh H, Huang ES, Levin P, Liu S, Brancati FL. Medication Use in Elderly US Adults with Diabetes and the Potential Practice Ramifications of Raising the Glycemic Target, NHANES 2003–2008. Paper presented at the 71st Scientific Sessions; 2011 June 24–28; San Diego, CA: American Diabetes Association; 2011.
   Google Scholar
• Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005;165(16):1910–1916.
   Google Scholar
• Lebovitz HE, Feinglos MN. Mechanism of action of the second- generation sulfonylurea glipizide. Am J Med. 1983;75(5B):46–54.
   Web of Science ®Google Scholar
• Kolterman OG, Gra RS, Shapiro G, Scarlett JA, Griffin J, Olesfsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33(4):346–354.
   PubMed Web of Science ®Google Scholar
• Groop L. Metabolic effects of sulfonylurea drugs. A review. Ann Clin Res. 1983:15 Suppl 37:16–20.
   Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303.
   PubMed Web of Science ®Google Scholar
• Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am. 1998;82(4):757–790.
   Web of Science ®Google Scholar
• Luna B, Hughes AT, Feinglos MN. The use of insulin secretagogues in the treatment of type 2 diabetes. Prim Care. 1999;26(4):895–915.
   Web of Science ®Google Scholar
• Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD004654.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32 Suppl 1:S13-S61.
   Google Scholar
• Luna B, Feinglos MN. Oral Agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63(9):1747–1756, 1759–1780.
   Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549.
   PubMed Web of Science ®Google Scholar
• Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab. 2007;9(6):767–780.
   PubMed Web of Science ®Google Scholar
• Hughes K, Aw TC, Kuperan P, Choo M. Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health. 1997;51(4):394–399.
   Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al; American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941–2948.
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411–418.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed September 30, 2011.
   Google Scholar
• Hanefeld M, Schaper F.. The role of alpha-glucosidase inhibitors (Acarbose). In: Mogensen CE, editor. Pharmacotheraphy of Diabetes: New Developments. Improving Life and Prognosis for Diabetic Patients. New York, NY: Springer; 2007:143–152.
   Google Scholar
• Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121(12):928–935.
   PubMed Web of Science ®Google Scholar
• Rodger NW, Chiasson JL, Josse RG, et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clin Invest Med. 1995;18(4):318–324.
   Web of Science ®Google Scholar
• McDougall C, McKay GA, Fisher M. Drugs for diabetes: part 6 GLP-1 receptor agonists. Br J Cardiol. 2011;18:167–169.
   Google Scholar
• McDougall C, McKay GA, Fisher M. Drugs for diabetes: part 5 DPP-4 inhibitors. Br J Cardiol 2011;18:130–132.
   Google Scholar
• Nauck M, Smith U. Incretin-based therapy: how do incretinmimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin EndocrinolMetab. 2009;23(4):513–523.
   Web of Science ®Google Scholar
• Siddiqui NI. Incretinmimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J. 2009;18(1):113–124. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19182763.
   Google Scholar
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung, and Blood Institute (US); 2004.
   Google Scholar
• Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Managt. 2010;6:883–903.
   PubMedGoogle Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-S82.
   PubMedGoogle Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–1762.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340(9):677–684.
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886–1892.
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91(12A):30H-37H.
   PubMedGoogle Scholar
• McFarlane SI. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev Cardiovasc Ther. 2009;7(11):1363–1371.
   PubMedGoogle Scholar
• Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010.
   PubMed Web of Science ®Google Scholar
• Mayor S. Calcium channel blockers associated with less diabetes. BMJ. 2006;333(7567):514.
   Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614–620.
   PubMed Web of Science ®Google Scholar
• Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15(7):820–825.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009.
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–1357.
   PubMed Web of Science ®Google Scholar
• Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641–648.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905–910.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive dose compared with moderate dose statin therapy. A Meta-analysis. JAMA. 2011;305(24):2556–2564.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Antiplatelet drugs. Med J Aust. 2003;178(11):568–574.
   Web of Science ®Google Scholar
• Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.
   PubMed Web of Science ®Google Scholar
• Richelsen B.. Obesity and pharmacological treatment. In: Mogensen CE, editor. Pharmacotheraphy of Diabetes: New Developments. Improving Life and Prognosis for Diabetic Patients. New York, NY: Springer; 2007:167–171.
   Google Scholar
• Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation. 1998;97(21):2099–2100.
   PubMedGoogle Scholar
• Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;25(1):148–198.
   PubMedGoogle Scholar
• Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes RelatMetab Disord. 1992;16(6):397–415.
   Web of Science ®Google Scholar
• Abraham WT. Preventing cardiovascular events in patients with diabetes mellitus. Am J Med. 2004;116 Suppl 5A:39S-46S.
   Google Scholar
• Castaneda C, Layne JE, Munoz-Orians L, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002;25(12):2335–2341.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care. 2002;25 Suppl 1:S64-S68.
   Google Scholar
• Stiegler RS, Zimmet PZ, Cameron AJ, et al. Lifestyle management: preventing Type 2 diabetes and cardiovascular complications. Therapy. 2009;6(4):489–496.
   Google Scholar
• The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383.
   Web of Science ®Google Scholar
• Redmon JB, Bertoni AG, Connelly S, et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care. 2010;33(6):1153–1158.
   PubMed Web of Science ®Google Scholar
• Wadden TA, West DS, Neiberg RH, et al. Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–722.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783–1789.
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Ilanne-Parikka P, Peltonen M, et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673–1679.
   PubMed Web of Science ®Google Scholar
• Eriksson KF, Lindagarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34(12):891–898.
   PubMed Web of Science ®Google Scholar
• Pan X, Li G, Hu Y, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Hamman RF, Edelstein SL, et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54(4):1150–1156.
   PubMed Web of Science ®Google Scholar
• Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67(2):152–162.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297.
   PubMed Web of Science ®Google Scholar
• Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque I, Figuls M, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;16(3):CD003054.
   Google Scholar
• Bo S, Ciccone G, Baldi C, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med. 2007;22(12):1695–1703.
   PubMed Web of Science ®Google Scholar
• Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individual with a family history of diabetes. Diabetes Care. 1998;21(3):350–359.
   PubMed Web of Science ®Google Scholar
• Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 month. Diabetes Res Clin Pract. 2001;52(1):29–43.
   Web of Science ®Google Scholar
• Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236.
   PubMed Web of Science ®Google Scholar
• Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med! Sci. 2006;61(10):1075–1081.
   Web of Science ®Google Scholar
• Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15–18.
   PubMed Web of Science ®Google Scholar
• Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macro- vascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39(12):1540–1545.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Schor S. The University Group Diabetes Program. A statistician looks at the mortality results. JAMA. 1971;217(12):1671–1675.
   Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23 Suppl 2:B21-B29.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Nathan DM. Navigating the choices for diabetes prevention. N Engl J Med. 2010;362(16):1533–1535.
   PubMed Web of Science ®Google Scholar
• Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspectivepio- glitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155(4):712–717.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective- pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772.
   PubMed Web of Science ®Google Scholar
• Abraira C, Duckworth W, McCarren M, et al; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17(6):314–322.
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27(7):1647–1653.
   PubMed Web of Science ®Google Scholar
• Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res. 2010;7(2):119–130.
   PubMed Web of Science ®Google Scholar
• Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997;157(2):181–188.
   PubMedGoogle Scholar
• Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394.
   PubMed Web of Science ®Google Scholar
• Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233–420.
   PubMed Web of Science ®Google Scholar
• Stamler R, Stamler J, Lindberg HA, et al. Asymptomatic hyperglycemia and coronary heart disease in middle-aged men in two employed populations in Chicago. J Chronic Dis. 1979;32(11–12):805–815.
   Google Scholar
• Stenhouse NS, Murphy BP, Welborn TA. Busselton population study: risk associated with asymptomatic hyperglycemia. J Chron Dis. 1979;32(11–12):693–698.
   Google Scholar
• Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P. Glucose tolerance and coronary heart disease: Helsinki policemen study. JChron Dis. 1979;32(11–12):729–745.
   Google Scholar
• Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycemia: the Whitehall Study. Br Med J. 1983;287(6396):867–870.
   PubMed Web of Science ®Google Scholar
• Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes. 1987;36(6):689–692.
   Web of Science ®Google Scholar
• Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol. 1991;133(6):565–576.
   Web of Science ®Google Scholar
• Vaccaro O, Ruth KJ, Stamler J. Relationship of postload plasma glucose to mortality with 19-year follow-up. Diabetes Care. 1992;15(10):1328–1334.
   Web of Science ®Google Scholar
• Balkau B, Eschwege E, Papoz L, et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ. 1993;307(6899):295–299.
   PubMedGoogle Scholar
• Tuomilehto J, Schranz A, Aldana D, Pitkaniemi J. The effect of diabetes and impaired glucose tolerance on mortality in Malta. Diabet Med. 1994;11(2):170–176.
   Web of Science ®Google Scholar
• Perry IJ, Wannamethee SG, Whincup PH, Shaper AG. Asymptomatic hyperglycaemia and major ischemic heart disease events in Britain. J Epidemiol Comm Health. 1994;48(6):538–542.
   Web of Science ®Google Scholar
• Shaten BJ, Kuller LH, Neaton JD. Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years. MRFIT Research Group. Prev Med. 1991;20(5):655–669.
   Web of Science ®Google Scholar
• Da Silva A, Widmer LK, Ziegler HW, Nissen C, Schweizer W The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheralartery disease, and subsequent mortality. J Chronic Dis. 1979;32(11–12):797–803.
   Google Scholar
• Hawthorne VM, Gilmour WH. Relationship of glucose to prevalence of ECG abnormalities at baseline and to 6-year mortality in Scottish males aged 45–64 yr. J Chron Dis. 1979;32(11–12):787–796.
   Google Scholar
• Reunanen A, Pyorala K, Aromaa A, Maatela J, Knekt P. Glucose tolerance and coronary heart disease in middle aged Finnish men: Social Insurance Institution’s Coronary Heart Disease Study. J Chron Dis. 1979;32(11–12):747–758.
   Google Scholar
• Cruz-Vidal M, Garcia-Palmieri MR, Costas R, Sorlie PD, Havlik RJ. Abnormal blood glucose and coronary heart disease: the Puerto Rico Heart Health Program. Diabetes Care. 1983;6(6):556–561.
   Web of Science ®Google Scholar
• Yarnell JW, Pickering JE, Elwood PC, et al. Does nondiabetichy- perglycemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol. 1994;47(4):383–388.
   Web of Science ®Google Scholar
• Schroll M, Hagerup L. Relationship of fastingblood glucose to prevalence of ECG abnormalities and 10-year risk of mortality from cardiovascular diseases in men born in 1914: from the Glostrup Population Studies. J Chron Dis. 1979;32(11–12):699–707.
   Google Scholar
• Ohlson LO, Svardsudd K, Welin L, et al. Fasting blood glucose and risk of coronary heart disease, stroke, and all-cause mortality: a 17-year follow-up study of men born in 1913. Diabetic Med. 1986;3(1):33–37.
   Web of Science ®Google Scholar
• Haheim LL, Holme I, Hjermann I, Leren P. Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects: 18-year follow-up of the Oslo study. Stroke. 1995;26(5):774–777.
   Web of Science ®Google Scholar
• Grabauskas VJ. Glucose intolerance as contributor to noncommunicable disease morbidity and mortality. WHO integrated program for community health in noncommunicable diseases. Diabetes Care. 1988;11(3):253–257.
   Web of Science ®Google Scholar
• Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl. 1985;701:38–52.
   PubMedGoogle Scholar
• Turnbull FM, Abraira C, Anderson RJ, et al; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298.
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–3264.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–764.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Gasowski J, Cells H, Fagard RH. Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am J Cardiol. 1998;82(9B):20R-22R.
   Web of Science ®Google Scholar
• Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. JHypertens. 2001;19(3):511–519.
   Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;355(9200):253–259.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
   PubMed Web of Science ®Google Scholar
• Chobanian AV Bakris GL, Black HR, et al. The seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572.
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153.
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P, Anderson C, et al; ONTARGET/ TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J. 2004;148(1):52–61.
   PubMed Web of Science ®Google Scholar
• Sawicki PT, Siebenhofer A. Beta-blockers and diabetes mellitus. J Clin Basic Cardiol. 2001;4:17–20.
   Google Scholar
• Niskanen L, Hedner T, Hansson L, Lanke J, Niklaston A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24(12):2091–2096.
   Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflu- methiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
   PubMed Web of Science ®Google Scholar
• Balamuthusamy S, Molnar J, Adigopula S, Arora R. Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. Am J Ther. 2009;16(2):133–142.
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med. 2004;116(1):44–49.
   Web of Science ®Google Scholar
• Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol. 1998;82(9B):9R-14R.
   Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645–652.
   PubMed Web of Science ®Google Scholar
• Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597–603.
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Liu LS. Subgroup analysis of the placebocontrolled Chinese trial on isolated systolic hypertension in the elderly. J Hypertens. 1999; 17 Suppl 3:S86. Available from: http://www.sciencedirect.com/science/article/pii/S0002934303006053-bbib13.
   Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713–720.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751–1756.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18(11):1671–1675.
   Web of Science ®Google Scholar
• Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431–436.
   Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542–549.
   PubMed Web of Science ®Google Scholar
• Vijan, S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138(7):593–602.
   PubMed Web of Science ®Google Scholar
• Fuller J, Stevens LK, Chaturvedi N, Holloway JF. WITHDRAWN: Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev. 2007;4:CD002188.
   Google Scholar
• Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 Suppl 2: B54-B64.
   Google Scholar
• Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211–220.
   PubMedGoogle Scholar
• Watkins PJ. ABC of diabetes, cardiovascular disease, hypertension, and lipids. BMJ. 2003;326:874–1186.
   Google Scholar
• Georg P, Ludvik B. Lipids and diabetes. J Clin Basic Cardiol. 2000;3:159–162.
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163.
   PubMed Web of Science ®Google Scholar
• Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478–1485.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–1630.
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29(4):499–508.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336(3):153–162.
   PubMed Web of Science ®Google Scholar
• GISSI Prevenzione Investigators (GruppoItaliano per lo Studio de llaSopravvivenzanellTnfartoMiocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J. 2000;1(12):810–820.
   Google Scholar
• Serruys PW, de Feyter P, Macaya C, et al; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215–3222.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–1158.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–2031.
   PubMed Web of Science ®Google Scholar
• Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26(10):2713–2721.
   PubMed Web of Science ®Google Scholar
• Pederson TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81(3):333–335.
   Web of Science ®Google Scholar
• Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15(7):820–825.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al; VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162(22):2597–2604.
   Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, et al; VA-HIT Study Group. Veterans Affairs high-density lipoprotein intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001 ;285 (12): 1585–1591.
   Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493–498.
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010;55(25):2878–2886.
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–126.
   PubMed Web of Science ®Google Scholar
• Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–2141.
   PubMed Web of Science ®Google Scholar
• De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–1304.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321(3):129–135.
   PubMed Web of Science ®Google Scholar
• ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992;268(10):1292–1300.
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–3272.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625–628.
   PubMed Web of Science ®Google Scholar
• Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338(21):1498–1505.
   Web of Science ®Google Scholar
• Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338(21):1488–1497.
   PubMed Web of Science ®Google Scholar
• The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998;97(24):2386–2395.
   Web of Science ®Google Scholar
• Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Am Heart J. 2000;139(4):563–566.
   Google Scholar
• The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339(7):436–443.
   PubMed Web of Science ®Google Scholar
• Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 ;357(9272): 1915–1924.
   Google Scholar
• Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation. 2001 ; 104(23): 2767–2771.
   Web of Science ®Google Scholar
• Theroux P, Alexander J Jr, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2001;102(20):2466–2472.
   Web of Science ®Google Scholar